Modification of PLGA nanoparticles for improved properties as a 99mTc-labeled agent in sentinel lymph node detection

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 8, 2013, Pages 598-606

  Subramanian, Suresh ^a   Pandey, Usha ^a   Gugulothu, Dalapathi ^b   Patravale, Vandana ^b   Samuel, Grace ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

^b INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

imaging; metastasis; nanoparticles; PLGA; sentinel lymph node; SLND

Indexed keywords

CARBOXYLIC ACID; MEBROFENIN; NANOPARTICLE; PENTETIC ACID; POLY [LACTIDE (CO GLYCOLIDE)]; STANNOUS CHLORIDE; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; FREEZE DRYING; ISOTOPE LABELING; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PURIFICATION; RADIOACTIVITY; RAT; SCINTIGRAPHY; SENTINEL LYMPH NODE METASTASIS;

ANIMALS; FEMALE; ISOTOPE LABELING; LACTIC ACID; LYMPH NODES; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; RADIONUCLIDE IMAGING; RATS; RATS, WISTAR; SENTINEL LYMPH NODE BIOPSY; TECHNETIUM TC 99M PENTETATE;

EID: 84884620452     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2013.1511     Document Type: Article

References (18)

1. Shayan R, Achen MG, Stacker SA. Lymphatic vessels in cancer metastasis: Bridging the gaps. Carcinogenesis 2006;27:1729.
2. Tobler NE, Detmar M. Tumor and lymph node lymphangiogenesis-Impact on cancer metastasis. J Leukoc Biol 2006;80:691.
3. Harish K. Sentinel node biopsy: Concepts and current status. Front Biosci 2005;10:2618.
4. Morton DL, Chan AD. The concept of sentinel node local.ization: How it started. Semin Nucl Med 2000;30:04.
5. Wilhelm AJ, Mijnhout GS, Franssen EJF. Radiopharmaceutical.s in sentinel lymph-node detection-An overview. Eur J Nucl Med 1999;26(Suppl):S36-S42.
6. Eshima D, Fauconnier T, Eshima L, et al. Radiopharmaceutical.s for lymphoscintigraphy: Including dosimetry and radiation considerations. Semin Nucl Med 2000;30:25.
7. Jain R, Dandekar P, Patraval.e V. Diagnostic nanocarriers for sentinel lymph node imaging. J Control Release 2009;138:90.
8. Núñ ez EGF, Faintuch BL, Teodoro R, et al. Influence of colloid particle profile on sentinel lymph node uptake. Nucl Med Biol 2009;36:741.
9. Subramanian S, Dandekar P, Jain R, et al. Technetium-99m-labeled poly(dl-lactide-co-glycolide) nanoparticles as an al.ternative for sentinel lymph node imaging. Cancer Biother Radiopharm 2010;25:637.
10. Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed 2006;17:247.
11. Ital.ia JL, Bhatt DK, Bhardwaj V, et al.. PLGA nanoparticles for oral. delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral.-. J Control Release 2007;119:197.
12. Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: An overview of biomedical. applications. J Control Release 2012;161:505.
13. Park J, Mattessich T, Jay SM, et al.. Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates. J Control Release 2011;156:109.
14. Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm 2008;364:298.
15. Jovanović MS, Brborić J, Vladimirov S, et al. Correlation between lipophilicity of the ligands and the hepatobiliary properties of the radiopharmaceutical.s: Approach to the development of new IDA derivatives. J Radioanal. Nucl Chem 2000;245:555.
16. Shen JM, Gao FY, Yin T, et al. cRGD-functional.ized polymeric magnetic nanoparticles as a dual.-drug delivery system for safe targeted cancer therapy. Pharmacol Res 2013;17:102.
17. Kocbek P, Obermajer, Cegnar M, et al. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal. antibody. J Control Release 2007;120:18.
18. Ratzinger G, Agrawal. P, Kö rner W, et al. Surface modification of PLGA nanospheres with Gd-DTPA and Gd-DOTA for high-relaxivity MRI contrast agents. Biomaterial.s 2010; 31:8716.